Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Bob More - aVenture Research

Bob More

AddedMar 31, 2024

UpdatedOct 12, 2026

Bob More

Bob More

Board Member, Nuon Therapeutics

Bob More's Career

Nuon Therapeutics

Series B$48M

Bob More's Co-Investors

Darren LachtmanCo-invested · CollX Seed

Scott Keeney / DJ SkeeCo-invested · CollX Seed

David AdelmanCo-invested · CollX Seed

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Bob More's Investments

1 investments since 2023

1 operating

Investments view

Group by

2023

1

CollX
Seed · February 2023$5.5M
Seed · February 2023

San Mateo, CA, US

Board Member· Board

Carticept Medical

$30MAlpharetta, GA, US

Board Member· Board

Moximed

Public$183.2MHayward, CA, US

Board Member· Board

Esprit Pharma

$269.5MEast Brunswick, NJ, US

Board Member· Board

Affinivax

$377.5MCambridge, MA, US

Board Member· Board

eGenesis

Series D$456MCambridge, MA, US

Board Member· Board

Frazier Life Sciences

Investment FirmPalo Alto, CA, US

Managing Director

Brad StadlerCo-invested · CollX Seed

Ryan SchinmanCo-invested · CollX Seed

Ryan SchinmanCo-invested · CollX Seed

Nat TurnerCo-invested · CollX Seed

Rogers HealyCo-invested · CollX Pre-Seed

People Similar to Bob More

Gino SantiniBoard Member · Collegium Pharmaceutical

Guido NeelsBoard Member · Bioventus

Leadership at Nuon Therapeutics

Joshua FunderBoard Member

Lawrence SteinmanFounder

Tito A SerafiniChief Scientific Officer

Similar to Nuon Therapeutics

Nuo TherapeuticsGaithersburg, MD, USMedical Devicesest. 1998Nuo TherapeuticsGaithersburg, MD, US · est. 1998

Nuo Therapeutics: Biotech firm innovating regenerative therapies for wound care and inflammation.

Public · $118.3M7

Nuvig TherapeuticsRedwood City, CA, USImmune Therapiesest. 2021Nuvig TherapeuticsRedwood City, CA, US · est. 2021

Nuvig Therapeutics: Innovating immune therapies for chronic inflammatory and autoimmune diseases.

Series A · $47M11

Orion BioScienceMissouri, USTherapiesest. 2012Orion BioScienceMissouri, US · est. 2012

Orion BioScience: A biotech start-up developing therapies for autoimmune diseases and inflammation.

NKT TherapeuticsWaltham, MA, USTherapeuticsest. 2008NKT TherapeuticsWaltham, MA, US · est. 2008

NKT Therapeutics: A US-based biotech firm dedicated to developing treatments for cancer and serious diseases.

Series A · $12M8

Leadership at Esprit Pharma

Joseph E SmithBoard Member

Similar to Esprit Pharma

UroGen PharmaNew York City, NY, USPharmaceuticalsest. 2004UroGen PharmaNew York City, NY, US · est. 2004

UroGen Pharma Ltd.: A clinical-stage biopharmaceutical firm innovating therapies for uro-oncology.

Public · $422.1M200

Union Springs PharmaceuticalsUnion Star, KY, USHealthcare Products, Pharmaceuticalsest. 2008Union Springs PharmaceuticalsUnion Star, KY, US · est. 2008

Union Springs Pharmaceuticals: A specialty OTC company developing and commercializing health care products in the US.

Series A · $5M200

Aytu BioPharmaEnglewood, CO, USPharmaceuticals, Therapeuticsest. 2015Aytu BioPharmaEnglewood, CO, US · est. 2015

Aytu BioPharma: A global specialty healthcare firm focusing on urological disorders and male infertility.

Public · $36M164

Spes PharmaceuticalsNorth Brunswick, NJ, USPharmaceuticalsest. 2017Spes PharmaceuticalsNorth Brunswick, NJ, US · est. 2017

Spes Pharmaceuticals Inc., a specialty biotech firm, develops and manufactures drugs and agricultural products.

Pre-Seed · $2M8

Leadership at Carticept Medical

Barbara D BoyanBoard Member

Brian HalakBoard Member

Tim PatrickBoard Member

Ryan DrantBoard Member

Gilbert PriceBoard Member

Similar to Carticept Medical

CartilageIrvine, CA, USMedical Devicesest. 2019CartilageIrvine, CA, US · est. 2019

Founded in 2019, Cartilage develops products to heal large and focal cartilage defects.

Leadership at Moximed

Anton CliffordCo-Founder

Josh MakowerBoard Member

Arthur FrankenBoard Member

Brigitte SmithBoard Member

Mohammed Shahzad Ahmed MalikBoard Member

Robert W Croce "Bob"Board Member

Similar to Moximed

ArticulinxCupertino, CA, USMedical Devicesest. 2007ArticulinxCupertino, CA, US · est. 2007

Articulinx, Inc.: US-based manufacturer of minimally invasive implants for hand osteoarthritis.

Series B · $12.2M30

Leadership at Affinivax

Steven M. AltschulerBoard Member

Kamran TavangarCo-Founder

George SiberBoard Member

Richard MalleyBoard Member

Fran HellerBoard Member

Steve BruggerCEO

Similar to Affinivax

GeoVax LabsSmyrna, GA, USVaccinesest. 2001GeoVax LabsSmyrna, GA, US · est. 2001

GeoVax Labs Inc.: A biotech firm specializing in the development and commercialization of vaccines for HIV-1 and other diseases.

Public · $28M14

Recent news

eGenesis Announces Clinical Update in Ongoing Expanded Access Study of EGEN-2784 in Patients with Kidney FailureeGenesis · 2026

eGenesis Appoints Glenn S. Vraniak as Chief Financial Officer and Jennifer Bergheiser as Chief Commercial OfficereGenesis · 2026

eGenesis Announces IND Clearance for EGEN-2784 in Kidney Transplant and Landmark Patient Updates in Ongoing Expanded Access StudyeGenesis · 2025

Leadership at eGenesis

Al WiegmanBoard Member

Boris NikolicBoard Member

Similar to eGenesis

Qihan Biotechest. 2017Qihan Biotechest. 2017

Qihan Biotech develops genome-edited cells and xenogeneic organs for therapy.

Series B · $117M

Makana Therapeuticsest. 2009Makana Therapeuticsest. 2009

Similar to Frazier Life Sciences

Frazier ManagementSeattle, WA, USest. 1991Frazier ManagementSeattle, WA, US · est. 1991

Frazier Healthcare Partners: A dedicated healthcare private equity and venture capital firm for 25 years.

Investment Firm114

Bioluminescence VenturesSan Francisco, CA, USest. 2022Bioluminescence VenturesSan Francisco, CA, US · est. 2022

US-based Bioluminescence, a biotech venture firm, invests in transformative science for next-gen medicines, focusing on breakthrough biology, drug discovery, and computational platforms.

Investment Firm7

Foresite CapitalSan Francisco, CA, USest. 2011Foresite CapitalSan Francisco, CA, US · est. 2011

Foresite Capital: A leading US venture capital & growth equity firm, headquartered in San Francisco.

Investment Firm68

Third Rock VenturesBoston, MA, USest. 2007Third Rock VenturesBoston, MA, US · est. 2007

Third Rock Ventures: A venture capital firm investing in life sciences and biotech in MA and CA.

Investment Firm148

ArticulinxCupertino, CA, USMedical Devicesest. 2007

ArticulinxCupertino, CA, US · est. 2007

Articulinx, Inc.: US-based manufacturer of minimally invasive implants for hand osteoarthritis.

Series B · $12.2M30

CoteraMenlo Park, CA, USMedical Devicesest. 2011CoteraMenlo Park, CA, US · est. 2011

Cotera: Innovating orthopedic solutions with implantable devices for knee osteoarthritis treatment.

Series A · $14.4M75

CartilaGenCoralville, IA, USBioactive Materialsest. 2015CartilaGenCoralville, IA, US · est. 2015

CartilaGen: A biotech startup developing bioactive materials to treat cartilage damage and osteoarthritis.

CoteraMenlo Park, CA, USMedical Devicesest. 2011

CoteraMenlo Park, CA, US · est. 2011

Cotera: Innovating orthopedic solutions with implantable devices for knee osteoarthritis treatment.

Series A · $14.4M75

NovoPedicsPrinceton, NJ, USMedical Devicesest. 2013NovoPedicsPrinceton, NJ, US · est. 2013

NovoPedics: Innovating implantable devices to alleviate pain and restore mobility in severe meniscal cases.

Pre-Seed · $500k5

AccufixWest Haven, CT, USMedical Devicesest. 2015AccufixWest Haven, CT, US · est. 2015

Accufix offers FDA-approved toe joint resurfacing systems, improving arthritis symptoms for an active lifestyle.

Series A · $5.3M4

CentivaxSouth San Francisco, CA, USTherapeutics, Vaccinesest. 2020

CentivaxSouth San Francisco, CA, US · est. 2020

Centivax: A healthcare agency offering biotech, pharma, medical device manufacturing & therapeutics.

Seed · $14.2M20

Moat BiotechnologyOklahoma City, OK, USVaccinesest. 2022Moat BiotechnologyOklahoma City, OK, US · est. 2022

Oklahoma City software firm & biopharmaceutical company developing innovative vaccines.

PathovaxBaltimore, MD, USBiotechnology, Vaccinesest. 2014PathovaxBaltimore, MD, US · est. 2014

PathoVax, a Johns Hopkins biotech start-up, specializes in commercializing RGVax in bioscience.

Daniel LynchBoard Member

Luhan YangBoard Member

Paul SekhriBoard Member

Makana Therapeutics develops gene-edited pig kidneys for kidney failure.

United TherapeuticsSilver Spring, MD, USPharmaceuticalsest. 1996United TherapeuticsSilver Spring, MD, US · est. 1996

United Therapeutics, a Maryland-based biotech firm, develops pharmaceuticals for vascular diseases using synthetic prostacyclin.

TransMedicsAndover, MA, USMedical Devicesest. 1998TransMedicsAndover, MA, US · est. 1998

TransMedics, a Massachusetts-based manufacturer, offers tech and clinical solutions for heart and lung transplants.

Public · $721.3M212